Novo Nordisk today announced that Saxenda (liraglutide 3 mg) is now available in the United States (US). Saxenda is the first glucagon-like peptide-1 (GLP-1) receptor agonist for weight management, approved in the US, EU and Canada. In the US, it is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI >=30 kg/m2) or who are overweight (BMI >=27 kg/m2) in the presence of at least one weight-related comorbid condition.

Saxenda was evaluated in the SCALE (TM) (Satiety and Clinical Adiposity-Liraglutide Evidence in Nondiabetic and Diabetic people) phase 3 clinical trial programme, which involved more than 5,000 study participants who have obesity (BMI >=30 kg/m2) or who are overweight (BMI >=27 kg/m2) with weight-related comorbidities. Trial data showed that Saxenda, in combination with a reduced-calorie diet and increased physical activity, resulted in greater weight loss than reduced calorie diet and physical activity alone.

For more details, go to: http://novonordisk.com/media/news-details.1913479.html